Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study). The study aims to evaluate the effectiveness of etentamig, an investigational drug, against standard therapies in treating relapsed or refractory multiple myeloma, a challenging blood cancer.
The intervention involves two groups: one receiving etentamig as an intravenous infusion and the other receiving standard available therapies, including combinations like carfilzomib and dexamethasone. The goal is to assess symptom changes and treatment efficacy.
This randomized, open-label study follows a parallel intervention model with no masking, focusing on treatment as its primary purpose. Around 380 participants will be enrolled across 140 global sites over a 3.5-year period.
The study began on May 19, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 29, 2025.
For investors, this study could impact AbbVie’s market position, especially if etentamig proves effective. Success could enhance AbbVie’s competitive edge in the multiple myeloma treatment market, potentially influencing stock performance positively.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.